Skip to main content

Table 2 Comparison between several observed histone PTM levels in this study and other studies (Chervona and Costa 2012)

From: A quantitative atlas of histone modification signatures from human cancer cells

Histone modification Observation in this study Observation in other studies
H3K4me3 Elevated in HCT116 colon line Elevated SMYD3 HMT levels in colorectal carcinomas [31]
H3K9me3 Reduced in NB4 and HL60 leukemia lines Reduced in promoter regions of acute myeloid leukemia patients [32]
H3K9me3 and H3K9me3K14ac Elevated in MDA-MB231 and MCF7 breast lines Elevated in circulating nucleosomes of breast cancer patients [33]
H3K18acK23un Reduced in 293 kidney and H1229 lung lines Reduced in poor prognosis kidney and lung cancer patients [34]
H3K27me3 Elevated in SAOS bone line Elevated EZH2 HMT expression in osteosarcomas [35]
H3K27me3 Elevated in MDA-MB231 and MCF7 breast lines Elevated EZH2 HMT expression in breast cancer [19]
H3K36me1 and H3K36me2 Elevated in HL60 leukemia line Elevated recruitment of NSD1 HMT translocation in acute myeloid leukemias [36]
H4K16ac Reduced in MDA-MB231 and MCF7 breast lines Reduced in patient breast tumors [28]
H4K20me2 Reduced in PC3 prostate line Reduced in metastatic and castration-resistant prostate cancer [37]
H4K20me3 Reduced in H1229 lung line Reduced in lung carcinoma progression [38]